Home/ Stocks/ SVRA

Savara Inc.

SVRA XNAS

$5.23 +0.07 (+1.36%) ▲ 15-min delayed

Open

$5.16

High

$5.23

Low

$5.12

Volume

816.1K

Market Cap

$1.07B

About Savara Inc.

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Sector: PHARMACEUTICAL PREPARATIONS Employees: 70 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-118,837,000	$-0.53
FY 2025	$0	$-118,837,000	$-0.53
Q3 2025	$0	$-29,561,000	$-0.14
Q1 2025	$0	$-26,639,000	$-0.12

Related Market News

No specific coverage for SVRA yet. Check out our latest market news or earnings calendar.

Get SVRA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Savara Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.